临床和认知评估在弗里德里希缺氧临床试验:一个审查
Álvaro Darriba1, Arnold Munnich2, Pedro Cardoso-Leite3
1Université Paris Cité, CNRS, UMR 8002 INCC, Paris, France.
Frontiers in neurology
|June 9, 2025
概括
弗里德里希缺血症 (FRDA) 临床试验需要更好的结果措施. 整合认知和语音评估可以改善对这种遗传性的治疗效果的评估.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 临床试验 临床试验
背景情况:
- 弗里德里希缺血症 (FRDA) 是最常见的遗传缺血症,是一种渐进的神经退行性疾病.
- 目前的治疗方法缺乏治愈方法,这凸显了需要有效的临床试验终点的需要.
研究的目的:
- 审查FRDA的临床试验,重点关注评估工具.
- 讨论整合被忽视的领域和定量认知/语音措施.
- 探索技术进步,以改善FRDA的评估.
主要方法:
- 审查现有的FRDA临床试验及其结果措施.
- 对认知评估工具的分析,强调定量,客观和基于时间的方法.
- 检查认知神经科学和技术的进步.
主要成果:
- 现有的FRDA试验通常依赖于有限的终点测量.
- 量化认知和语音评估未得到充分利用,但有价值.
- 技术创新为更全面的评估提供了潜力.
结论:
- 加强结果测量,包括认知和语音评估,对于FRDA试验至关重要.
- 整合新技术可以提高治疗疗效评估的准确性和全面性.
- 这些进展有望改进试验设计,改善FRDA患者的临床护理.
相关概念视频
Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
961
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
961


